Bitargeting and ambushing nanotheranostics

References

• Acharya S, Dilnawaz F, Sahoo SK. 2009. Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy. Biomaterials. 30:5737–5750.
   PubMed Web of Science ®Google Scholar
• Baldwin A, Huang Z, Jounaidi Y, Waxman DJ. 2003. Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer. Arch Biochem Biophys. 409: 197–206.
   PubMed Web of Science ®Google Scholar
• Byrne JD, Betancourt T, Brannon-Peppas L. 2008. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Del Rev. 20:1615–1626.
   Google Scholar
• Chen CS, Lin JT, Goss KA, He Y, Halpert JR, Waxman DJ. 2004. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol. 65:1278–1285.
   PubMed Web of Science ®Google Scholar
• Chen L, Yu LY, Waxman DJ. 1997. Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. Cancer Res. 57:4830–4837.
   PubMed Web of Science ®Google Scholar
• Chen ZG. 2010. Small-molecule delivery by nanoparticles for anticancer therapy. Trends Mol Med. 16:594–602.
   PubMed Web of Science ®Google Scholar
• Davis ME. 2009. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol Pharmaceutics. 6:659–668.
   PubMed Web of Science ®Google Scholar
• Diltemiz SE, Say R, Büyüktiryaki S, Hur D, Denizli A, Ersöz A. 2008. Quantum dot nanocrystals having guanosine imprinted nanoshell for DNA recognition. Talanta. 75:890–896.
   PubMed Web of Science ®Google Scholar
• Dobrovolskaia MA, Aggarwal P, Hall JB, McNeil SE. 2008. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharmaceutics. 5:487–495.
   PubMed Web of Science ®Google Scholar
• Elliott RL, Elliott MC, Wang F, Head JF. 1993. Breast carcinoma and the role of iron metabolism. A cytochemical, tissue culture, and ultrastructural study. Ann NY Acad Sci. 698:159–166.
   PubMed Web of Science ®Google Scholar
• Gewin V. 2009. Big opportunities in a small world. Nature. 460: 540–541.
   Google Scholar
• Grainger SJ, Serna JV, Sunny S, Zhou Y, Deng CX, El-Sayed MEH. 2010. Pulsed ultrasound enhances nanoparticle penetration into breast cancer spheroids. Mol Pharmaceutics. 7:2006–2019.
   PubMedGoogle Scholar
• Gültekin A, Diltemiz SE, Ersoz A, Sariozlu NY, Denizli A, Say R. 2009. Gold-silver nanoclusters having dipicolinic acid imprinted nanoshell for Bacillus cereus spores recognition. Talanta. 78: 1332–1338.
   Google Scholar
• Jounaidi Y, Waxman DJ. 2000. Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy. Cancer Res. 60:3761–3769.
   PubMed Web of Science ®Google Scholar
• Jounaidi Y, Waxman DJ. 2001. Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy. Cancer Res. 61:4437–4444.
   PubMed Web of Science ®Google Scholar
• Jounaidi Y, Waxman DJ. 2004. Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res. 64:292–303.
   PubMed Web of Science ®Google Scholar
• Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T. 2000. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metabol Dispos. 28:1457–1463.
   PubMed Web of Science ®Google Scholar
• Kumar S, Chen CS, Waxman DJ, Halpert JR. 2005. Directed evolution of mammalian cytochrome P450 2B1. J Biol Chem. 280: 19569–19575.
   PubMed Web of Science ®Google Scholar
• Liang M, Liu X, Cheng D, Liu G, Dou S, Wang Y, et al. 2010. Multimodality nuclear and fluorescence tumor imaging in mice using a streptavidin nanoparticle. Bioconjugate Chem. 21:1385–1388.
   PubMed Web of Science ®Google Scholar
• Liu HY, Gao X. 2011. Engineering monovalent quantum dot-antibody bioconjugates with a hybrid gel system. Bioconjugate Chem. 22: 510–517.
   Google Scholar
• McFadyen MCE, Melvin WT, Murray GI. 2004. Cytochrome P450 enzymes: novel options for cancer therapeutics. Mol Cancer Ther. 3:363–371.
   PubMed Web of Science ®Google Scholar
• Messerschmidt SKE, Musyanovych A, Altvater M, Scheurich P, Pfizenmaier K, Landfester K, Kontermann RE. 2009. Targeted lipid-coated nanoparticles: delivery of tumor necrosis factor-functionalized particles to tumor cells. J Control Release. 137: 69–77.
   PubMed Web of Science ®Google Scholar
• Mo Y, Lim LY. 2005. Paclitaxel-loaded PLGA nanoparticles: potentiation of anticancer activity by surface conjugation with wheat germ agglutinin. J Control Release. 108:244–262.
   PubMed Web of Science ®Google Scholar
• Park H, Lee S, Kim JH, Park K, Kim K, Kwon IC. 2008. Polymeric nanomedicine for cancer therapy. Prog Polym Sci. 33:113–137.
   Web of Science ®Google Scholar
• Patra CR, Bhattacharya R, Mukhopadhyay D, Mukherjee P. 2010. Fabrication of gold nanoparticles for targeted therapy in pancreatic cancer. Adv Drug Del Rev. 62:346–361.
   PubMed Web of Science ®Google Scholar
• Peterson JA, Ebel RE, O’Keeffe DH, Matsubara T, Estabrook RW. 1976. Temperature dependence of cytochrome P-450 reduction. A model for NADPH-cytochrome P-450 reductase: cytochrome P-450 interaction. J Biol Chem. 251:4010–4016.
   PubMed Web of Science ®Google Scholar
• Roy A, Singh MS, Upadhyay P, Bhaskar S. 2010. Combined chemo-immunotherapy as a prospective strategy to combat cancer: a nanoparticle based approach. Mol Pharmaceutics. 7:1778–1788.
   PubMed Web of Science ®Google Scholar
• Say R, Kılıç GA, Özcan AA, Hur D, Yilmaz F, Kutlu M, et al. 2011. Investigation of photosensitively bioconjugated targeted quantum dots for the labeling of Cu/Zn superoxide dismutase (SOD1) in fixed cells and tissue sections. Histochem Cell Biol. 135:523–530.
   Google Scholar
• Say R. 2009. Photosensitive aminoacid-monomer linkage and bioconjugation applications in life sciences and biotechnology. PCT/IB2009/055707, Applied 11 Dec. 2009.
   Google Scholar
• Schmidt R, Baumann F, Knupfer H, Brauckhoff M, Horn LC, Schonfelder M, et al. 2004. CYP3A4, CYP2C9 and CYP2B6 expression and ifosfamide turnover in breast cancer tissue microsomes. British J Cancer. 90:911–916.
   PubMed Web of Science ®Google Scholar
• Schwartz PS, Chen CS, Waxman DJ. 2003. Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy. Cancer Gene Ther. 10:571–582.
   PubMed Web of Science ®Google Scholar
• Werlin R, Priester JH, Mielke RE, Kramer S, Jackson S, Stoimenov PK, et al. 2011. Biomagnification of cadmium selenide quantum dots in a simple experimental microbial food chain. Nature Nanotechnol. 6:65–71.
   PubMed Web of Science ®Google Scholar
• Wu PC, Su CH, Cheng FY, Weng JC, Chen JH, Tsai TL, et al. 2008. Modularly assembled magnetite nanoparticles enhance in vivo targeting for magnetic resonance cancer imaging. Bioconjugate Chem. 19:1972–1979.
   Google Scholar